About InDanio Bioscience

About company

InDanio Bioscience Inc., is a privately-held in vivo drug discovery company dedicated to developing New Chemical Entities (NCEs) targeting the pharmaceutically-important Nuclear Receptor (NR) protein families. Their proprietary, Ligand Trap system, which includes 48 transgenic zebrafish lines, each singularly expressing one of the 48 human Nuclear Receptors, allows simultaneous assessment of drug delivery, stability, specificity, tissue-selectivity and toxicity. Selective, highest-value target lines are being used to identify, extract and characterize new hormonal regulators, as well as to identify new tissue-selective drugs, co-factors and mechanisms of action for each Nuclear Receptor.